Logo

Beyond Air’s LungFit PH Receives the US FDA’s Approval for the Treatment of Hypoxic Respiratory Failure in Term and Near-Term Neonates

Share this
Beyond Air’s LungFit PH Receives the US FDA’s Approval for the Treatment of Hypoxic Respiratory Failure in Term and Near-Term Neonates

Beyond Air’s LungFit PH Receives the US FDA’s Approval for the Treatment of Hypoxic Respiratory Failure in Term and Near-Term Neonates

Shots:

  • The US FDA has approved LungFit PH to treat hypoxic respiratory failure in term and near-term neonates. The device uses the company’s patented Ionizer technology to generate unlimited, on-demand nitric oxide using ambient air. LungFit PH is expected to be available in the H1’23
  • LungFit PH creates electrical discharge pulses b/w 2 electrodes in a plasma chamber using a compressor to circulate air in the space
  • It produces nitric oxide with low NO2 as a byproduct by ionising nitrogen and oxygen molecules with the power of a 60W lightbulb. This is the 1st FDA-approved product and eliminates the need for traditional nitric oxide tanks in hospitals setting and the associated burdens to providers

Ref: GlobalNewswire | Image: Beyond Air

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions